Holen Sie sich die Stockscreener-App
722.94
14.84%
93.43
Handel nachbörslich:
723.00
0.06
+0.01%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt IDXX?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$629.51
Offen:
$693
24-Stunden-Volumen:
1.65M
Relative Volume:
3.13
Marktkapitalisierung:
$57.84B
Einnahmen:
$4.04B
Nettoeinkommen (Verlust:
$985.66M
KGV:
60.17
EPS:
12.0143
Netto-Cashflow:
$774.34M
1W Leistung:
+11.67%
1M Leistung:
+14.54%
6M Leistung:
+53.20%
1J Leistung:
+73.25%
1-Tages-Spanne:
$691.73
$735.00
1-Wochen-Bereich:
$622.08
$735.00
52-Wochen-Spanne:
$356.14
$735.00
Idexx Laboratories Inc Stock (IDXX) Company Profile
Firmenname
Idexx Laboratories Inc
Sektor
Branche
Telefon
(207) 556-0300
Adresse
ONE IDEXX DRIVE, WESTBROOK, ME
Vergleichen Sie IDXX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IDXX
Idexx Laboratories Inc
|
722.94 | 50.36B | 4.04B | 985.66M | 774.34M | 12.01 |
|
TMO
Thermo Fisher Scientific Inc
|
564.88 | 213.17B | 43.74B | 6.58B | 6.11B | 17.31 |
|
DHR
Danaher Corp
|
214.06 | 152.13B | 24.27B | 3.50B | 5.02B | 4.8589 |
|
A
Agilent Technologies Inc
|
144.69 | 41.49B | 6.79B | 1.22B | 1.09B | 4.2644 |
|
IQV
Iqvia Holdings Inc
|
213.88 | 36.86B | 15.90B | 1.28B | 2.21B | 7.2842 |
Idexx Laboratories Inc Stock (IDXX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-31 | Hochstufung | Stifel | Hold → Buy |
| 2025-10-01 | Eingeleitet | UBS | Neutral |
| 2025-08-05 | Bestätigt | BTIG Research | Buy |
| 2025-07-01 | Eingeleitet | Jefferies | Buy |
| 2024-12-02 | Eingeleitet | Leerink Partners | Outperform |
| 2024-07-25 | Eingeleitet | BTIG Research | Buy |
| 2024-01-30 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2023-12-07 | Eingeleitet | Exane BNP Paribas | Outperform |
| 2023-12-04 | Hochstufung | Cleveland Research | Neutral → Buy |
| 2023-08-02 | Herabstufung | Atlantic Equities | Overweight → Neutral |
| 2022-07-25 | Herabstufung | Stifel | Buy → Hold |
| 2022-07-21 | Hochstufung | Goldman | Neutral → Buy |
| 2022-07-12 | Eingeleitet | Piper Sandler | Overweight |
| 2022-05-05 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-02-08 | Eingeleitet | Atlantic Equities | Overweight |
| 2021-11-18 | Eingeleitet | Morgan Stanley | Overweight |
| 2021-08-05 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-07-12 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-02-17 | Eingeleitet | Barclays | Overweight |
| 2019-09-09 | Eingeleitet | Goldman | Neutral |
| 2019-05-23 | Eingeleitet | Guggenheim | Buy |
| 2018-11-02 | Bestätigt | BofA/Merrill | Buy |
| 2018-05-07 | Bestätigt | Stifel | Buy |
| 2018-01-16 | Eingeleitet | Piper Jaffray | Overweight |
| 2017-08-23 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2017-07-28 | Hochstufung | CL King | Neutral → Buy |
| 2017-02-03 | Herabstufung | Feltl & Co. | Hold → Sell |
| 2016-09-29 | Fortgesetzt | BofA/Merrill | Neutral |
| 2016-08-16 | Bestätigt | Stifel | Buy |
| 2016-08-03 | Hochstufung | Northcoast | Sell → Neutral |
| 2016-07-20 | Bestätigt | Canaccord Genuity | Buy |
| 2016-04-19 | Bestätigt | Canaccord Genuity | Buy |
| 2016-04-01 | Eingeleitet | CL King | Neutral |
| 2016-03-21 | Bestätigt | Stifel | Buy |
| 2016-02-04 | Eingeleitet | Credit Suisse | Outperform |
| 2015-10-29 | Bestätigt | Stifel | Buy |
| 2015-08-28 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2015-08-13 | Bestätigt | Stifel | Buy |
| 2015-07-23 | Bestätigt | Canaccord Genuity | Buy |
Alle ansehen
Idexx Laboratories Inc Aktie (IDXX) Neueste Nachrichten
Decoding IDEXX Laboratories Inc (IDXX): A Strategic SWOT Insight - GuruFocus
IDEXX Laboratories Reports Strong Q3 2025 Results - TipRanks
Idexx Laboratories stock reaches 52-week high at $693.00 By Investing.com - Investing.com Nigeria
IDEXX Laboratories Inc. (IDXX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
IDEXX Laboratories Jumps 15% on Q3 Earnings Beat - AOL.com
IDEXX Laboratories (IDXX) Reports Strong Q3 2025 Financial Perfo - GuruFocus
Leerink Partners Maintains IDEXX Laboratories Inc(IDXX.US) With Buy Rating, Raises Target Price to $785 - 富途牛牛
Daily Market Wrap: Top Stocks – Amazon, Cipher, and Idexx Laboratories - TheStreet
Why Idexx Laboratories Stock Surged by Almost 15% Today - AOL.com
Why Idexx Laboratories Stock Surged by Almost 15% Today - The Motley Fool
IDEXX Laboratories Inc. stock outperforms competitors on strong trading day - MarketWatch
IDXX Stock Surges: What this Means - StocksToTrade
IDEXX Laboratories Inc (IDXX) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo Finance
IDEXX Laboratories stock price target raised to $775 by Stifel on growth outlook - Investing.com Nigeria
Earnings call transcript: IDEXX Labs Q3 2025 beats expectations, stock surges By Investing.com - Investing.com South Africa
Earnings call transcript: IDEXX Labs Q3 2025 beats expectations, stock surges - Investing.com Canada
Stock Markets Diverged As Amazon And IDEXX Stood Out - Finimize
Kenvue, IDEXX Laboratories, Freshpet And Other Big Stocks Moving Higher On Monday - Benzinga
Micron, IDEXX among market cap stock movers on Monday - Investing.com
IDEXX Laboratories’ Stock Soars: Growth or Bubble? - StocksToTrade
Leerink Partners IDEXX Laboratories' Price Target to $785 From $745 - MarketScreener
Research Alert: CFRA Keeps Buy Rating On Shares Of Idexx Laboratories, Inc. - 富途牛牛
Idexx Laboratories Extends Rally Following Upbeat Q3 Earnings, Outlook - Benzinga
Transcript : IDEXX Laboratories, Inc., Q3 2025 Earnings Call, Nov 03, 2025 - MarketScreener
IDEXX Laboratories Inc reports results for the quarter ended September 30Earnings Summary - TradingView
Idexx Laboratories stock reaches 52-week high at $693.00 - Investing.com
IDEXX Laboratories (IDXX): Inside the Pet Diagnostics Leader’s 2025 Breakout 🚀 - ts2.tech
Pet Spending Lifts IDEXX Laboratories To Higher Forecasts - Finimize
Earnings Summary: Highlights of IDEXX’s Q3 2025 report - AlphaStreet
IDEXX Laboratories, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 - MarketScreener
IDEXX Laboratories (IDXX) Surges as Q3 Results Beat Expectations - GuruFocus
Is IDEXX Laboratories, Inc. (NASDAQ:IDXX) Potentially Undervalued? - Yahoo Finance
IDEXX Reports Strong Growth And Lifts 2025 Forecast - Finimize
IDEXX raises annual forecasts as pet owners spend more on preventive care - MarketScreener
IDEXX Laboratories stock pops on Q3 beats, raised outlook (IDXX:NASDAQ) - Seeking Alpha
IDEXX Laboratories Q3 2025 Earnings: EPS of $3.40 and Revenue of $1,105 Million Surpass Estimates - GuruFocus
IDEXX (IDXX) Exceeds Revenue Expectations in Q3 - GuruFocus
IDEXX Labs shares jump as pet diagnostics firm beats Q3 estimates - Investing.com
Why retail investors favor IDEXX Laboratories Inc. stock2025 Performance Recap & Advanced Swing Trade Entry Plans - newser.com
IDEXX Laboratories Q3 Earnings, Revenue Rise; Raises 2025 Guidance - MarketScreener
Building trade automation scripts for IDEXX Laboratories Inc.Market Growth Summary & Technical Pattern Based Signals - newser.com
Idexx: Q3 Earnings Snapshot - WKYC
Veterinary diagnostics company beats IDEXX Q3 revenue estimates, hikes FY forecasts - MarketScreener
(IDXX) IDEXX Laboratories Expects 2025 Revenue Range $4.27B to $4.30B, vs. FactSet Est of $4.24B - MarketScreener
(IDXX) IDEXX Laboratories Expects 2025 EPS Range $12.81$13.01, vs. FactSet Est of $12.62 - MarketScreener
Earnings Flash (IDXX) IDEXX Laboratories, Inc. Reports Q3 Revenue $1.11B, vs. FactSet Est of $1.07B - MarketScreener
Earnings Flash (IDXX) IDEXX Laboratories Posts Q3 Comparable EPS $3.22, vs. FactSet Est of $3.12 - MarketScreener
IDEXX Laboratories Announces Third Quarter Results - TradingView
Welch & Forbes LLC Sells 829 Shares of IDEXX Laboratories, Inc. $IDXX - MarketBeat
Crystal Rock Capital Management Sells 600 Shares of IDEXX Laboratories, Inc. $IDXX - MarketBeat
iA Global Asset Management Inc. Acquires 565 Shares of IDEXX Laboratories, Inc. $IDXX - MarketBeat
Finanzdaten der Idexx Laboratories Inc-Aktie (IDXX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.14%
1.53%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):